Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Neprilysin Inhibition to Reduce Myocardial Fibrosis in HFpEF
NCT06536309Phase 4Withdrawn
- Sponsor
- Brigham and Women's Hospital
- Start
- Aug 2026
- Primary completion
- Aug 2026
- Modality
- Small Molecules
01
Overview
A Phase 4 trial of sacubitril + valsartan in heart failure with preserved ejection fraction (HFpEF), sponsored by Brigham and Women's Hospital. Planned start Aug 2026; status: withdrawn.
02
Drugs
sacubitril + valsartan
03
Conditions
heart failure with preserved ejection fraction (HFpEF)
Beyond the preview
Go deeper on NCT06536309.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06536309.